



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/025,732	12/19/2001	William M. Pardridge	0180.0029	8416
7590 07/01/2004		EXAMINER		
David J. Oldenkamp, Esq.			LAMBERTSON, DAVID A	
Shapiro, Borenstein & Dupont LLP Suite 700			ART UNIT	PAPER NUMBER
233 Wilshire Boulevard			1636	
Santa Monica, CA 90401			DATE MAILED: 07/01/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.



Advisory Action

Application No.	Applicant(s)		
10/025,732	PARDRIDGE, WILLIAM M.		
Examiner	Art Unit		
David A. Lambertson	1636		

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

THE REPLY FILED 08 June 2004 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCE) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 CFR 1.114.	4
PERIOD FOR REPLY [check either a) or b)]	
 a)	0
Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee un 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set fort (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce a earned patent term adjustment. See 37 CFR 1.704(b).	der h in
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.	
2. The proposed amendment(s) will not be entered because:	
(a) Method they raise new issues that would require further consideration and/or search (see NOTE below);	
(b) ☐ they raise the issue of new matter (see Note below);	
(c) \boxtimes they are not deemed to place the application in better form for appeal by materially reducing or simplifying issues for appeal; and/or	the
(d) they present additional claims without canceling a corresponding number of finally rejected claims.	
NOTE: See Continuation Sheet.	
3. Applicant's reply has overcome the following rejection(s):	
4. Newly proposed or amended claim(s) would be allowable if submitted in a separate, timely filed amendm canceling the non-allowable claim(s).	ent
5. The a) affidavit, b) exhibit, or c) request for reconsideration has been considered but does NOT place the application in condition for allowance because:	ıe
6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection.	
7.⊠ For purposes of Appeal, the proposed amendment(s) a)⊠ will not be entered or b)□ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.	
The status of the claim(s) is (or will be) as follows:	
Claim(s) allowed:	
Claim(s) objected to:	
Claim(s) rejected: <u>1-10 and 22-29</u> .	
Claim(s) withdrawn from consideration:	
8. ☐ The drawing correction filed on is a) ☐ approved or b) ☐ disapproved by the Examiner.	
9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s)	
10. Other:	
JAMES KETTER PRIMARY EXAMINER	

Continuation Sheet (PTOL-303) 10/025,732

Application No.

Continuation of 2. NOTE: The instant claims have been amended to remove the limitaiton "an eye-specific gene." As such, the claims now read on a broader scope of genes that can be present in the claimed composition of matter. This broadened scope would require a new search and new consideration with regard to the patentability of the invention, after prosecution on the merits has been closed. Because the amendments After Final will require a new search and new consideration, the amendment will not be entered.

Additionally, the current arguments are predicated on the entry of the After Final amendment. Indeed, on page 7 of Applicant's response it is indicated that "In order to overcome any possible misinterpetation of the terms created by applicant as discussed above, applicant amends the claims to remove the use of the term "eye-specific" or "eye specific therapeutic" gene and substitutes in its place a "gene that expresses a therapeutic or diagnostic agent for said ocular cell." Because the arguments are predicated on an amendment that has not been entered, the arguments cannot be addressed.